1. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Pharmacoeconomic guidelines around the world. Lawrenceville: ISPOR; 2015. Available at: http://www.ispor.org/PEguidelines/index.asp . Accessed Jan 2015.
2. Roberts M, Russell LB, Paltiel AD, Chambers M, McEwan P, Krahn M, et al. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2. Med Decis Mak. 2012;32(5):678–89.
3. European Medicines Agency (EMA). Annual report 2014. London: EMA; 2015. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Annual_report/2015/04/WC500186306.pdf . Accessed Jan 2015.
4. Jenkins J. CDER approved many innovative drugs in 2014. Blog posting in FDA Voice. Silver Spring: US FDA; Jan 2015. Available at: http://blogs.fda.gov/fdavoice/index.php/2015/01/cder-approved-many-innovative-drugs-in-2014/ . Accessed Jan 2015.
5. Sullivan SD, Alfonso-Cristancho R, Carlson J, Mallya U, Ringold S. Economic consequences of sequencing biologics in rheumatoid arthritis: a systematic review. J Med Econ. 2013;16(3):391–6.